Q-omics provides the consensus-scored TEX43 profile across patient tissues and cancer cell-line models. TEX43 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, TEX43 is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, TEX43 RNA expression shows 7,158 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, COAD, and TGCT as cancer lineages where TEX43 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TEX43 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TEX43 survival associations across molecular data types. TEX43 RNA expression shows survival associations in the most cancer types (13), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TEX43 RNA expression–survival associations across cancer types. High TEX43 expression shows unfavorable associations in KIRP, STAD and CHOL, but favorable associations in ACC, COAD and BLCA. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .011). Together, the overview and detailed table identify KIRP as the clearest survival context for TEX43 RNA expression.
This table summarizes TEX43 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for TEX43. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TEX43 shows lower tumor expression in COAD and READ and higher tumor expression in KICH, BLCA, LIHC and ESCA. The COAD box plot shows higher TEX43 RNA expression in normal versus tumor tissue (log2 FC = −1.620, t-test p < 0.001).
This table shows molecular features associated with TEX43 in patient tissues and cancer cell lines. In patient samples, TEX43 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, TEX43 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in LIVER and LUNG_NSCLC_LUSC.
